Discover our Pipeline
From a well-known MoA towards a validated Partnership & Licensing strategy
Our portfolio reflects the potential of Cilastatin (CIL) in different indications and serves as the basis for further expansion towards future R&D projects where inhibiting inflammatory processes, reducing ROS and cytokine production and apoptosis will be the key.
CIL is safe molecule, with 30 year+ extensive clinical usage in a combination with an antibiotic and with well-known safety and PK data in humans, not existing as stand-alone and with no room for off-label use. Phase I Clinical Trial successfully performed with CIL alone. Well stablished MoA with more than 25 years of extensive research and publications.
CIL alone has been shown to prevent renal damage induced by drug treatments including chemotherapeutics, immunosuppressants and other antibiotics.
In patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC-cisplatin), it has been shown that CIL (imipenem/cilastatin) may exert nephroprotective effects.
Phase II currently in progress by our partner Arch Biopartners: PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins.
Cilastatin a new drug for the treatment of Glaucoma and Retinal Neurodegenerative diseases.
CILASTATIN (CIL) has shown an unprecedented Neuroprotection of the Retina in unilateral laser-induced ocular hypertension (OHT) mice model of glaucoma, preventing Retinal Ganglion Cells (RGCs) damage without reducing intraocular pressure (IOP). CIL has anti-Inflammatory effects in the Retina and diminishes the microglial response.
| Program | Indication | Pre-clinical | Phase I | Phase II | Phase III | Partners | |
| TLP-01 |
|
Licensed to: |
|||||
| TLP-02 |
|
Licensed to: |
|||||
| TLP-03 |
|
wholly-owned | |||||
| TLP-04 |
|
wholly-owned | |||||